19.07.2018
Evotec AG DE0005664809
DGAP-News: EVOTEC RECEIVES MILESTONE PAYMENT FOR START OF PHASE II TRIAL IN ITS MULTI-TARGET ALLIANCE WITH BAYER
DGAP-News: Evotec AG / Key word(s): Miscellaneous
EVOTEC RECEIVES MILESTONE PAYMENT FOR START OF PHASE II TRIAL IN ITS
MULTI-TARGET ALLIANCE WITH BAYER
19.07.2018 / 07:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Hamburg, Germany, 19 July 2018:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
announced today that its multi-target alliance with Bayer in the field of
endometriosis has advanced a promising small molecule into Phase II clinical
development for the treatment of chronic cough, resulting in a payment of
EUR 4 m to Evotec.
Chronic cough is a major global health burden and has a significant impact
on the quality of life of millions of people. Currently, no therapies are
approved for the treatment of chronic cough.
This new trial has been initiated following positive results from a Phase I
study which is part of the ongoing Bayer-Evotec endometriosis alliance. The
potential to treat patients with a persistent chronic cough was highlighted
due to the nature and expression of the target protein being originally
explored for the treatment of endometriosis. The clinical Phase I trial in
healthy volunteers started in 2017 and has now advanced into Phase II trial
in chronic cough in July 2018.
The Evotec-Bayer multi-target discovery alliance was entered in October
2012. The goal of this collaboration is to discover three clinical
candidates within the alliance. Both parties contribute innovative drug
targets and high-quality technology infrastructures and share the
responsibility for early research and pre-clinical characterisation of
potential clinical candidates in the disease area of endometriosis. Since
the beginning of the collaboration, six first-in-class non-hormonal
pre-clinical candidates have been generated; three of those progressed into
Phase I clinical trials in endometriosis and chronic cough.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "Since we
began collaborating with Bayer in 2012, the joint teams have combined
cutting-edge science, significant drug discovery expertise, and a shared
commitment to bring new therapeutics options to the millions of patients.
With the advancement of our first novel drug candidate into Phase II studies
we continue to grow and build out our strong partnered pipeline. We look
forward to further advancing our target portfolio across a developing range
of potential therapeutic indications, especially for patients with
unexplained chronic cough new and effective treatment options are urgently
needed."
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, infectious
diseases, diabetes and complications of diabetes, pain, inflammation, and
oncology and. On this basis, Evotec has built a broad and deep pipeline of
more than 80 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi and UCB and
development partnerships with e.g. Sanofi in the field of diabetes, Pfizer
in the field of tissue fibrosis and Celgene in the field of
neurodegenerative diseases. For additional information, please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking statements
are neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
19.07.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard);
Regulated Unofficial Market in Dusseldorf, Hamburg,
Hanover, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
705995 19.07.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT